Oct. 26, 2015—23andMe has launched a new version of its personal genome service. Following two years of work with the FDA, extensive user comprehension testing and a complete redesign, 23andMe’s offering includes carrier status, wellness, trait, and ancestry reports. The announcement follows an October 2013 FDA order that 23andMe stop marketing the previous version of its direct-to-consumer genomics service.
“We’ve worked with the FDA for nearly two years to establish a regulatory path for direct-to-consumer genetic testing. We are a better company with a better product as a result of our work with the FDA,” 23andMe cofounder and CEO Anne Wojcicki said in a statement. “This is an incredibly dynamic time in genetics and we’re excited to be at the leading edge of bringing genetics directly to individuals as they begin to learn about their 23 pairs of chromosomes.”
For $199, customers receive a detailed genetic report that is designed to be easy to understand. The company says that ease of use was validated by user testing. The service includes:
- More than 60 health, ancestry, wellness, and personal trait reports.
- Reports on genetic research and new genetic discoveries.
- Personalized insights based on analysis of 650,000 genetic variations.
- Segment-level data for advanced genetic genealogy research.
- The chance to find and connect with DNA relatives in a database of more than 1 million customers.
Existing customers will be transitioned to the “new experience” as quickly as possible, said a company statement. The transition of some customers will be dependent on validation and local requirements.
23andMe’s service also offers consenting customers the chance to participate in ongoing research by answering survey questions. In turn, they will receive insights along the way to help learn more about their genetics, see early findings from 23andMe research, and learn how they compare with others. A new 23andMe Research mobile app will also be available on the Apple App Store.